Award Number:  W81XWH-07-1-0648  

TITLE:  Evaluating the Role of Genetic Markers in Prostate Cancer Progression:  A Multi-Ethnic Cohort Experience  

PRINCIPAL INVESTIGATOR:  Sara S. Strom, PhD  

CONTRACTING ORGANIZATION:  University of Texas MD Anderson Cancer Center  
Houston, TX 77030  

REPORT DATE:  October 2010  

TYPE OF REPORT:  Annual  

PREPARED FOR:  U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland  21702-5012  

DISTRIBUTION STATEMENT:  (Check one)  

☐ Approved for public release; distribution unlimited  

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**REPORT TITLE:** Evaluating the Role of Genetic Markers in Prostate Cancer Progression: A Multi-Ethnic Cohort Experience

**AUTHORS:** Sara S. Strom, PhD

**PERFORMING ORGANIZATION:**
University of Texas
MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, TX 77030

**ABSTRACT:**
Most prostate cancer (PCa) research has focused on risk, little is known about predictors of progression and even less about how these factors differ by ethnicity/race. There are strong racial disparities in mortality with African-Americans twice as likely to die from PCa compared to Caucasians; very little data are available in Hispanics. Our goal is to identify markers of PCa progression in a multiethnic cohort (773 Caucasians, 361 African-Americans and 246 Mexican-Americans). Medical records for all participants have been abstracted, and we are updating vital status using the National Death Index. We are multiplexing the genotyping assays to optimize the utilization of our archived specimens, and all DNA extractions have been completed. Our research may help explain ethnic/racial disparities in PCa progression and provide direction towards eliminating these disparities and may guide future studies to develop ethnic/racial specific interventions to improve outcome in the most common cancer in American men.
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>6</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Conclusion</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Appendices</td>
<td>8</td>
</tr>
</tbody>
</table>
INTRODUCTION:
There is a paucity of information regarding markers/factors associated with prostate cancer (PCa) outcome in the United States, especially how these factors differ among racial/ethnic groups. African-American men are more likely to have poorer outcome relative to age and stage-matched Caucasian patients; and very little is known about prognosis and even less about factors that could predict progression among Hispanics. The overall goal of our research project is to identify molecular, epidemiological and clinical markers related to prostate cancer (PCa) progression in a multiethnic cohort of 1,380 PCa patients (773 Caucasians; 361 African Americans, and 246 Mexican Americans).

BODY:
Task 1  Patient follow-up. (Months 1-30)

a. Update patient follow-up data by checking clinical schedules and medical charts for updated information. Using a validated medical abstraction form, all patient charts will be abstracted.

b. Signed medical releases of information will be requested for care received outside of our institution. Copies of medical records will be requested.

c. Death certificates will be obtained for all participants identified as deceased.

d. Patients’ self-reported recurrences (and subsequent treatments) and secondary cancers will be verified.

e. Data will be entered into existing databases.

All medical record abstractions for all prostate cancer patients who have received follow-up care at our institution have been completed. Institutional patient records were matched by the institutional Tumor Registry to determine which of our study participants had a return visit to the institution within the past year, and the most recent visit was abstracted and the medical record abstraction was updated for each participant. All medical records were abstracted using the standardized form attached as Appendix A. The most recent clinical follow-up date at our institution is determined; this date is used as the “last date of contact” at the University of Texas MD Anderson Cancer Center (UTMDACC). All abstractions were performed using a paper form and are currently being entered into an existing clinical database.

For patients for whom we do not have recent follow-up information at UTMDACC, we are continuing to conduct telephone interviews to request these data. The greatest challenge we continue to face is locating and contacting these individuals we last spoke with several years ago. We are utilizing several options for obtaining updated contact information; including general internet searches, reverse address searches, and credit records. To-date, we have successfully completed 120 follow-up interviews by phone. The protocol to verify potentially valid contact information includes calling the individual at least 5 times at different times of the day, as well as on weekends, if needed; the calls are conducted using the telephone script included as Appendix B. In addition, if these call attempts are not successful, we send a letter to the patient at the last known valid address (with address
correction requested) explaining that we are trying to follow-up with them regarding their participation in a study and requesting that they contact us at their earliest convenience. Updated health and risk factor information is collected by trained interviewers, using a questionnaire modified for this project (Appendix C).

Patients who are receiving follow-up care outside of UTMDACC are asked to sign a medical record release form (Appendix D) to allow us to obtain copies of the relevant records from their healthcare providers. Outside medical records are abstracted using the same standardized forms as used for UTMDACC records. Clinical recurrences and related treatments are noted on the abstraction forms and verified by the study clinical personnel. We are preparing for one last update of vital status using data from the National Death Index.

Task 2  Evaluate Constitutional Markers of Genetic Susceptibility. (Months 1-30)

a. Genotyping assays for all genes will be established, tested and validated by the Department of Epidemiology Genotyping Core (Months 1-24).
   We have refined our methodology to multiplex the assays for the genotyping.

b. Biological samples for all participants will be located and retrieved from study archive freezers (Months 1-3).
   Using our laboratory tracking database, biological samples for this study have been identified, located and retrieved from our freezer facility. All samples for this study have been transferred to the genotyping facility.

c. DNA will be extracted from banked specimens (Months 1-12).
   DNA has been extracted from all of the banked specimens. DNA quality has been tested for the extracted samples to ensure the success of the analyses. Extracted DNA has been successfully used for the genotyping assays performed and reported below.

d. DNA samples will be plated for genotyping analyses – half the samples will be done in Year 2 and the other half will be done in Year 3 (Months 13 & 25)
   All samples have been quantified, standardized, plated, and submitted for genotyping.

e. Genotyping will be done for half the samples in Year 2 (Months 13-24) and the other half in Year 3 (Months 25-30).
   To-date, we have completed preliminary genotyping 611 cases for MMP-1, 615 for e-cadherin, 433 for beta-2-adrenergic receptor, and 725 for cyclin D1. In our preliminary analyses, we have found significant differences with respect to genotypic frequency between racial/ethnic groups for MMP-1, beta-2-adrenergic receptor and cyclin D1. Due to recent improvements in technology, we have changed our genotyping methodology to utilize the Illumina platform for the final
genotyping analyses. From recently published genome wide association studies (GWAS) and validation studies of PCa risk, we have identified 75 polymorphisms (rs10033464, rs1016343, rs10486567, rs10498792, rs10896449, rs10934853, rs10993994, rs11228565, rs12155172, rs12500426, rs12621278, rs1327301, rs1447295, rs1465618, rs1512268, rs16901979, rs16902094, rs17021918, rs17181170, rs1859962, rs2660753, rs2735839, rs3123078, rs345013, rs4242382, rs4242384, rs4430796, rs445114, rs4466137, rs4962416, rs5759167, rs5945572, rs5945619, rs6465657, rs651164, rs6545977, rs6983267, rs7127900, rs7130881, rs721048, rs7501939, rs7679673, rs7931342, rs8102476, rs9311171, rs9364554, rs9623117, rs401681, rs2736098, rs2928679, rs6983561, rs13254738, rs7000448, rs10090154, rs424382, rs979200, rs7837328, rs3891248, rs7005795, rs13252298, rs620861, rs12543663, rs1571801, rs12418451, rs10778826, rs11861609, rs4782780, rs1799950, rs3737559, rs11649743) for which we will analyze their role in prostate cancer progression. In addition, we are collaborating with several multi-ethnic consortiums (led by Tim Rebbeck at University of Pennsylvania, Brian Henderson at the University of Southern California, and Ros Eeles at the Institute of Cancer Research Royal Cancer Hospital-London) to conduct genome-wide association studies, particularly in African-Americans.

**Task 3 Final Analysis and Preparation of Reports.** (Months 30-36)
We are currently awaiting the final genotyping results to initiate our analyses of these data. These results will be presented at the 2011 IMPaCT meeting.

**KEY RESEARCH ACCOMPLISHMENTS:**
There are no key research accomplishments to report at this time; we are still in the process of finalizing follow-up and genotyping data. No interim analyses have been performed, nor were any planned to be conducted at this time-point.

**REPORTABLE OUTCOMES:**
Currently, there have been no manuscripts, presentations, patents or licenses applied for based on this award. Additionally, there have not been any degrees supported by this award; no cell lines, tissue or serum repositories developed; no informatics applied for based on work from this award; no employment opportunities applied for and/or received based on experience/training supported by this award. An abstract presenting these data has been submitted for the 2011 IMPaCT meeting. Preliminary data (numbers of participants with follow-up information) have been included in 2 recent grant proposals: U01-Genome-wide association study of prostate cancer in African Americans (Henderson), funded; U19 –Trans-disciplinary cancer genomics research: post-GWA initiative (Henderson/Eeles), funded.

**CONCLUSION:**
Our research may help explain ethnic/racial disparities in PCa progression and
provide direction towards eliminating these disparities. Additionally, our results may guide future studies to develop ethnic/racial specific interventions (i.e., behavioral, clinical) to improve outcome in the most common cancer in American men.

REFERENCES: N/A
APPENDIX A:

Medical record abstraction form
Medical Records Abstraction Form

Name

MDACC# ____________________________
____________________________________ MDA registration date _____/_____/____

Address
________________________________________

Date of birth  ____/_____/____

Age at diagnosis __________________ years

Phone number _______________________

Ethnicity

☐ White
☐ Hispanic
☐ African-American
☐ Asian
☐ Other _____________________________

☐ Mexican
☐ Cuban
☐ S. American
☐ Other _________________________________

Vital status

☐ Living
☐ Deceased → Date of death ____/_____/____

Place of death ________________

Cause of death _______________________

Last date of contact ____/_____/____

Place of contact ___________________________

Height: _______cm

_______ft/_________inches

Weight: _______ kg

_______lbs

Prostate cancer diagnosis

Date of diagnosis ____/_____/____

Place of diagnosis: MDACC ☐ Yes

☐ No

Diagnostic tests

☐ Biopsy

☐ TURP

☐ Chest x-ray

☐ Bone scan

☐ CT scan

☐ Other _______ ☐ POS ☐ NEG

Where ____________________________

When ____/_____/____

Comments

_________________________________________
### Clinical stage of diagnosis
- Organ confined disease
- Regional disease
- Metastatic disease → date of confirmation ____/____/____

Sites:
- Bones
- Liver
- Adrenal gland
- Kidney
- Brain
- Other

### TNM stage
- **T1** → 0 □ a □ b □ c
- **T2** → a □ b □ c
- **T3** → a □ b □ c
- **T4**
- **N** → 0 □ 1 □ 2 □ 3
- **M** → 0 □ 1

Summary _________________________________

Comments ______________________________________________________________________
_____________________________________________________________________________

### Laboratory results

#### Post-treatment values
- Most recent post-treatment PSA value ____________ ng/ml Date ____/____/____
- Follow-up PSA Values ________________________ ng/ml Date ____/____/____
- Follow-up PSA Values ________________________ ng/ml Date ____/____/____
- Follow-up PSA Values ________________________ ng/ml Date ____/____/____
- Follow-up PSA Values ________________________ ng/ml Date ____/____/____
- Follow-up PSA Values ________________________ ng/ml Date ____/____/____
- Initial post-treatment PSA value ______________ ng/ml Date ____/____/____

#### Pre-treatment values
- Highest pre-treatment PSA value ____________ ng/ml Date ____/____/____
- Initial pre-treatment PSA value ____________ ng/ml Date ____/____/____

Comments: ___________________________________________________________________
### Pathology report

**Specimen type**:  
- [ ] Prostatectomy

**MDACC grade**:  
- [ ] I  
- [ ] II  
- [ ] III  
- [ ] IV  
- [ ] Other ______________________

**Seminal Vesicle involvement**:  
- [ ] Yes  
- [ ] No  

**S/Margins**:  
- [ ] Positive  
- [ ] Negative

### Combined Gleason score

- [ ] 2  
- [ ] 3  
- [ ] 4  
- [ ] 5  
- [ ] 6  
- [ ] 7  
- [ ] 8  
- [ ] 9  
- [ ] 10

Dominant focus size /size _________________ cm  
Prostate volume _________________ cm

**Tumor locations**:  
- [ ] Peripheral zone  
- [ ] Central zone  
- [ ] Transitional zone  
- [ ] AFM zone

**Comments**:  
________________________________________________________________________________
________________________________________________________________________________

---

### Pathology report

**Specimen type**:  
- [ ] Biopsy

**MDACC grade**:  
- [ ] I  
- [ ] II  
- [ ] III  
- [ ] IV  
- [ ] Other ______________________

**Combined Gleason score**:  
- [ ] 2  
- [ ] 3  
- [ ] 4  
- [ ] 5  
- [ ] 6  
- [ ] 7  
- [ ] 8  
- [ ] 9  
- [ ] 10

Dominant focus size /size _________________ cm  
Prostate volume _________________ cm

**Tumor locations**:  
- [ ] Peripheral zone  
- [ ] Central zone  
- [ ] Transitional zone  
- [ ] AFM zone

**Comments**:  
________________________________________________________________________________
________________________________________________________________________________

---

### History of prostate cancer screening

- [ ] No

- [ ] Yes  
  - Type of screening test:  
    - [ ] Prostate-specific antigen (PSA)
    - [ ] Digital rectal examination (DRE)
    - [ ] Trans-rectal ultrasound (TRUS)
    - [ ] Other ______________________

**Presence of urinary symptoms**:  
- [ ] Yes  
- [ ] No

**Comments**:  
________________________________________________________________________________
### Prostate cancer treatment received

- **Radical prostatectomy Type** → **Radical Retropubic Prostatectomy (RRP)** Date _____/_____/_____
- **Radical perineal prostatectomy (RPP)**
- **Nerve-sparing**
- **Pelvic lymphadenectomy**

- **Orchiectomy** → Date _____/_____/_____
- **Cryosurgery** → Date _____/_____/_____

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Onset of treatment</th>
<th>End of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy (EBRT)</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Surveillance</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
<tr>
<td>Other (specify)</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
</tbody>
</table>

**Comments**
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

### Complications of treatment

**Urinary Incontinence**

- **No**
- **Yes** → Uses sanitary pad

<table>
<thead>
<tr>
<th>Treatment received</th>
<th>Uses sanitary pad</th>
<th>Number of pads/day</th>
<th>Date <em><strong><strong>/</strong></strong></em>/_____</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td></td>
<td>Number of pads/day</td>
<td>Date <em><strong><strong>/</strong></strong></em>/_____</td>
</tr>
</tbody>
</table>

**Post-treatment status (1yr.)** Number of pads/day ________ Date _____/_____/_____

**Impotence**

- **No**
- **Yes** → Treatment received

**Post-treatment status (1yr.)** Treatment received

**Urinary retention**

- **No**
- **Yes** → Treatment received

**Other**
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
### Comorbid conditions prior to diagnosis of prostate cancer

- **Diabetes (IDDM, NIDDM)**
  - Date of diagnosis ___/___/___
- **Hemorrhage**
  - Date of diagnosis ___/___/___
- **Hypertension**
  - Date of diagnosis ___/___/___
- **Peptic ulcer disease**
  - Date of diagnosis ___/___/___
- **Congestive heart failure**
  - Date of diagnosis ___/___/___
- **Pancreatitis**
  - Date of diagnosis ___/___/___
- **Myocardial infarction**
  - Date of diagnosis ___/___/___
- **Cholelithiasis**
  - Date of diagnosis ___/___/___
- **Stroke**
  - Date of diagnosis ___/___/___
- **Alcoholism**
  - Date of diagnosis ___/___/___
- **Chronic obstructive pulmonary disease**
  - Date of diagnosis ___/___/___
- **Lupus erythematosus**
  - Date of diagnosis ___/___/___
- **Other __________________**
  - Date of diagnosis ___/___/___

### Other pertinent information

**Recurrence of prostate cancer**

- **No**
- **Yes**
  - Date of diagnosis ___/___/___

  - Place of diagnosis ___________________
  - Type of treatment ___________________
  - Basis of diagnosis ___________________

### Diagnostic tests

- **Biopsy**
  - POS
  - NEG
- **TURP**
  - POS
  - NEG
- **Chest x-ray**
  - POS
  - NEG
- **Bone scan**
  - POS
  - NEG
- **CT scan**
  - POS
  - NEG
- **Other ______***
  - POS
  - NEG
### Conditions diagnosed after diagnosis of prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Place of diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of treatment received</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last clinic visit    Date  _____/_____/_____
APPENDIX B:

Follow-up telephone recruitment script

SCRIPT 1 (Speaking to person who answers phone) –

Hello, my name is (INTERVIEWER’S NAME) and I am calling on behalf of MD Anderson Cancer Center, here in Houston. May I please speak with (PATIENT’S NAME)?

➤ NOT AVAILABLE – Verify (PATIENT’S NAME) lives at this residence. Ask “Is there a time that I could call back and speak with him?” OR “would you please ask him to call me (INTERVIEWER’S NAME) at (PHONE NUMBER) at his earliest convenience? Thank you for your assistance.

➤ YES – Thank you…(Wait for (PATIENT’S NAME) come to phone) Hello, my name is (INTERVIEWER’S NAME) and I am calling on behalf of MD Anderson Cancer Center, here in Houston. You participated in one of our prostate cancer studies a few years ago, and we are conducting a follow-up study to see how you are doing. Would it be all right with you if I asked you a few questions about your health and updated your information?

• NO – thank you for your time. If you change your mind and would like to participate, please contact me (INTERVIEWER’S NAME) at (PHONE NUMBER).

• YES – I want to let you know that answering these questions is completely voluntary, and you may decide not to answer any or all of them. (Administer risk factor questionnaire (Appendix D))

Following each call, the interviewer logs each call made onto the tracking log for each file, documenting the date, time, phone number dialed, and with whom they spoke. These logs are maintained in the individual patient’s study chart, kept in a locked office coded by study identification number.
APPENDIX C:

Follow-Up questionnaire
STUDY NUMBER: _______________  DATE OF PC DIAGNOSIS: _____/_____/_____

MED RECORD/PATIENT #: ___________  DATE OF BASELINE INTERVIEW: _____/_____/_____

PATIENT RECEIVING FOLLOW-UP CARE AT MDACC: ___(1) YES  DATE OF MOST RECENT MDACC VISIT: _____/_____/_____
___(2) NO

_____________________________________________  HOME PHONE: (____)_______________
FIRST NAME                      M.I.                    LAST NAME
_____________________________________________  WORK PHONE: (____)_______________
STREET ADDRESS
_____________________________________________  SSN: _____________________________
CITY                         STATE                                ZIP CODE

INTERVIEW DATE: _____/_____/_____  INTERVIEWER’S INITIALS: ______________

WHO IS COMPLETING QUESTIONNAIRE?  O PATIENT            O PROXY
IF PATIENT IS DECEASED, DATE OF DEATH _________________________  COUNTY & STATE OF DEATH ____________________
As you may remember, you participated in a study of prostate cancer. We are currently updating our information, and we wanted to see how you are doing. Do you have a few moments to talk to me now or when can I call you back?

1. Are you currently being followed-up for your previous prostate cancer? _______ YES (1) _______ NO (2)

2. Where are/were you receiving follow-up care?

3. When was your most recent follow-up visit? ________________ (Date)

When was the last time you had (the following test(s))? What were the results?

<table>
<thead>
<tr>
<th>Test</th>
<th>Most Recent Date</th>
<th>Result (most recent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Prostate Specific Antigen/ (PSA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Ultrasound (TRUS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Biopsy or Transurethral Resection of Prostate (TURP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other (specify)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8. Have you received any prostate treatment since you were last seen at MD Anderson/Kelsey-Seyboldt/VAMC/Dr. ______________ (select provider) in ______________ (fill in last date)?
   _____ (1) YES  _____(2) NO  
   Skip to Q. 12

9. When and where were/are you receiving treatment? (e.g., MD/Clinic Name, Address, Phone #)

Office Note: Obtain signed medical release of information
10. What type(s) of treatment did you receive? (e.g., radiation, hormone shots, hormone pills, chemotherapy)

______________________________________________________________________________________________________
______________________________________________________________________________________________________

11. Why was the treatment necessary?

______________________________________________________________________________________________________
______________________________________________________________________________________________________

Have you ever been told by a doctor or another health care professional that you have any of the following conditions?

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>BEEN TOLD?</th>
<th>DATE/AGE DIAGNOSED</th>
<th>TREATMENT/MEDICATION NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>12. Diabetes (or sugar in urine)</td>
<td>(1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Hypertension (high blood pressure)</td>
<td>(1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Angina (angina pectoris)</td>
<td>(1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Heart attack (myocardial infarction)</td>
<td>(1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. Any other kind of heart condition or disease (not mentioned above)</td>
<td>(1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPECIFY: __________________</td>
<td>(2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONDITION</td>
<td>BEEN TOLD?</td>
<td>DATE/AGE DIAGNOSED</td>
<td>TREATMENT/MEDICATION NAME</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
<td>--------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>17. High cholesterol</td>
<td>____ (1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>_____ (2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Arthritis TYPE:</td>
<td>_____ (1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>_____ (2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Any other cancer(s)?</td>
<td>_____ (1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPECIFY</td>
<td>_____ (2) NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20. Any other condition(s)? SPECIFY</td>
<td>_____ (1) YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>_____ (2) NO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TOBACCO**

The next questions are about smoking.

- **Previous Smoking Status**
  - ____ Current
  - ____ Former
  - ____ Never

21. Since your prostate cancer diagnosis, has your smoking status changed? ____ (1) YES ____ (2) NO

22. Are you currently smoking cigarettes? ____ (1) YES ____ (2) NO → When did you stop? _____________ (Year)

23. On average, how many cigarettes per day do you/did you smoke? __________________________
24. Have you taken any supplements, over the counter medications or prescription medications at least once a month since your diagnosis? This would include all vitamins, minerals, herbal and non-herbal supplements of any kind.

(2) No, GO TO Q. 26

(1) Yes, Fairly regularly

(3) Yes, but NOT regularly

25. Please list the names of any supplements (including vitamins, minerals and herbal supplements), over-the-counter medications or prescription medications that you have taken. Also include the number of pills or tablets taken daily, weekly, monthly or yearly?

<table>
<thead>
<tr>
<th>Supplement, Over-the-counter or prescription medication</th>
<th>Number per Day</th>
<th>Number per Week</th>
<th>Number per Month</th>
<th>Number per Year</th>
<th>Rarely / Never (✓)</th>
<th>How many years?</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand: ____________________________ Name on bottle: ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brand: ____________________________ Name on bottle: ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brand: ____________________________ Name on bottle: ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brand: ____________________________ Name on bottle: ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brand: ____________________________ Name on bottle: ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### DIET

*The following questions are regarding diet changes*

Since your diagnosis, have you changed your consumption of the following types of foods?

<table>
<thead>
<tr>
<th>FOOD TYPE</th>
<th>INCREASED</th>
</tr>
</thead>
<tbody>
<tr>
<td>26. Fat</td>
<td>___(1) increased</td>
</tr>
<tr>
<td></td>
<td>___(2) decreased</td>
</tr>
<tr>
<td></td>
<td>___(3) no change</td>
</tr>
<tr>
<td>27. Fruits</td>
<td>___(1) increased</td>
</tr>
<tr>
<td></td>
<td>___(2) decreased</td>
</tr>
<tr>
<td></td>
<td>___(3) no change</td>
</tr>
<tr>
<td>28. Vegetables</td>
<td>___(1) increased</td>
</tr>
<tr>
<td></td>
<td>___(2) decreased</td>
</tr>
<tr>
<td></td>
<td>___(3) no change</td>
</tr>
<tr>
<td>29. Fiber</td>
<td>___(1) increased</td>
</tr>
<tr>
<td></td>
<td>___(2) decreased</td>
</tr>
<tr>
<td></td>
<td>___(3) no change</td>
</tr>
<tr>
<td>30. Soy products</td>
<td>___(1) increased</td>
</tr>
<tr>
<td></td>
<td>___(2) decreased</td>
</tr>
<tr>
<td></td>
<td>___(3) no change</td>
</tr>
</tbody>
</table>

31. Are there any comments that you would like to add about your diet or about the way you have changed your diet?

________________________________________________________________________________________________________________________________________________

________________________________________________________________
### FAMILY HISTORY

In this section, I would like to ask you some questions about your family.

#### FAMILY HISTORY PRE-CODE:

Previously reported family members WITH cancer:

<table>
<thead>
<tr>
<th>Sex</th>
<th>Relative</th>
<th>Side of Family</th>
<th>Type of Cancer</th>
<th>Sex</th>
<th>Relative</th>
<th>Side of Family</th>
<th>Type of Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

32. Previously, you told us that your ____________________________ (insert previous history here) had cancer, have any other immediate family members been diagnosed with cancer? ___ YES (1) ___ NO (2)  

**Go to Q. 34**

33. Would you please give us some information about these NEW family members diagnosed with cancer? (DON’T include those previously reported)

<table>
<thead>
<tr>
<th>Rel Code</th>
<th>Sex</th>
<th>Relative</th>
<th>Rel UIN</th>
<th>When was he/she born?</th>
<th>What kind of cancer?</th>
<th>ICD-9</th>
<th>When was he/she diagnosed?</th>
<th>Is he/she still living?</th>
<th>When did he/she die?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(1) Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2) No</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(1) Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2) No</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(1) Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2) No</td>
<td></td>
</tr>
</tbody>
</table>
In this section, I would like to ask you some questions about your current occupation.

<table>
<thead>
<tr>
<th>What is your job or occupation?</th>
<th>Years employed</th>
<th>Major duties</th>
<th>Equipment used (Any Chemicals?)</th>
<th>Work done by company</th>
<th>SIC</th>
<th>OCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Job:</td>
<td><em><strong>To</strong></em>_</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Spec
If we need additional information from you in the future, can we contact you by telephone?  ____ (1) YES  ____ (2) NO

This is the end of our interview. I would like to thank you for your help with our research. If you have any questions that I or Dr. Strom can answer in the future, please feel free to contact us. We would also like to verify that we have your current address correctly recorded. We have your current address as: **READ ADDRESS FROM FILE RECORD**

Is this address correct?  ____ (1) YES  ____ (2) NO  (If NO, please provide correct information below)

<table>
<thead>
<tr>
<th>First Name</th>
<th>Middle Name</th>
<th>Last Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
<th>Zip Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Also, so that we may keep contact with you, would you please give me that name, address, and telephone number of a person who does not live with you who will know your whereabouts in the future:

<table>
<thead>
<tr>
<th>First Name</th>
<th>Middle Name</th>
<th>Last Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
<th>Zip Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Thank you once again for your time and help with our research project. If we have any more questions in the future, we hope we can call you again.
INTERVIEW ASSESSMENT

Date of interview: ____/____/____                          Interviewer’s Initials: __________________

Time Interview began: __________________                   Time Interview ended: ________________

1. Respondent’s cooperation was:
   ______ Very Good (1)
   ______ Good (2)
   ______ Fair (3)
   ______ Poor (4)

2. The quality of the interview was:
   ______ Highly Reliable (1)
   ______ Generally Reliable (2)
   ______ Questionable (3)
   ______ Unsatisfactory (4)

Please write comments about the interview: ____________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
APPENDIX D:
Medical release of information form
AUTHORIZATION FOR DISCLOSURE OF HEALTH INFORMATION

(1) I hereby authorize ____________________________ to disclose the following information from the health records of:

Patient Name: ________________________________________________________________________________

<table>
<thead>
<tr>
<th>Last</th>
<th>First</th>
<th>MI.</th>
<th>Date of Birth</th>
<th>MDA #</th>
</tr>
</thead>
<tbody>
<tr>
<td>______________</td>
<td>______________</td>
<td>__________</td>
<td>______________</td>
<td>______</td>
</tr>
</tbody>
</table>

Address: ____________________________________________________________________________________

Street  City  State  Zip Code

Phone

covering the period of healthcare from _________________ to ___________________.

(2) Information to be disclosed:

- Complete Health Record
- Primary Medical Evaluation
- Progress Notes
- X-Ray Reports
- Discharge Summary
- Consultation Reports
- Laboratory Tests
- Radiotherapy Notes
- Chemotherapy Notes
- Nurse’s Notes

- Other (specify) __________________________________________

I understand that this will include information relating to (check if applicable):

- Acquired Immunodeficiency Syndrome (AIDS) or infection with HIV (Human Immunodeficiency Virus)
- Psychiatric care
- Treatment for alcohol and/or drug abuse

(3) This information is to be disclosed to: Dr. Sara Strom

Investigator’s signature

UT MD Anderson Cancer Center

1515 Holcombe, Houston, Texas  77030

for the purpose of: **Medical Record completion for research protocol M91-004**.
(4) I understand this authorization may be revoked in writing at any time, except to the extent that action has been taken in reliance on this authorization. Unless otherwise evoked, this authorization will expire on the following date, event, or condition:

__________________________________________________________________

(5) The facility, its employees, officers, and physicians are hereby released from any legal responsibility or liability for disclosure of the above information to the extent indicated and authorized herein.

Signed: ____________________________________________________________

or ________________________________________________________________

(Signed) (Relationship to Patient) (date)

(Signed) (Relationship to Patient) (date)

SUPPORTING DATA: N/A